identity of the inducing factor(s) in tissue homogenates has not been unequivocally resolved.
To determine whether degenerating tissues might contain non-αS components that could induce pathology in M83
+/− mice, we conducted brain injections of young M83 +/− mice with spinal cord (SC) homogenates prepared from motor-impaired M83 +/+ mice, motor-impaired transgenic mice expressing the G93A variant of human superoxide dismutase-1 (hSOD-1), and healthy non-transgenic (NTg) mice. The intracerebral (hippocampal) injection of SC homogenates from affected M83 +/+ mice served as a positive control and these mice were sacrificed at 120 days post-injection (DPI), at which time αS pathology was predominantly observed in the forebrain (hippocampus and entorhinal cortex), but also distributed in the midbrain, brainstem, and SC (Supplemental Fig. 1 ; Table 1 ). For the intrahippocampal injections of SC homogenates from paralyzed G93A hSOD-1 and NTg mice, the study design was to sacrifice mice at 180 DPI to assess pathology levels. Unexpectedly, two of the M83 +/− mice injected with SC homogenate from paralyzed G93A hSOD-1 mice developed motor impairments prior to 180 DPI, leading to complete hind limb paralysis (Table 1) . These two mice and the other three asymptomatic mice, sacrificed at 180 DPI, all had prominent αS inclusion pathology with a distribution typical of aged M83 mice, with additional pathology observed in the hippocampus ( Fig. 1 ; Table 1 ). Even more surprisingly, 4 out of the 5 M83 +/− mice injected in the hippocampus with SC homogenates from NTg mice also developed M83-type motor impairment and paralysis (Table 1) . M83
+/− mice injected with either G93A hSOD-1 or NTg SC homogenates showed similar levels of αS inclusion pathology ( Fig. 1 ; Table 1 ). One pre-symptomatic mouse from each of these cohorts was sacrificed at 105 DPI to survey for earlier pathologic induction and these also presented with αS inclusion
The injection of tissue homogenates from diseased animals into naïve animals to induce a neurodegenerative phenotype is a feature that defines "prion-like" transmission. Several recent studies have demonstrated that transgenic mice expressing human A53T-α-synuclein (αS; Line M83), respond to injections of CNS tissue homogenates containing abundant αS pathology by accelerated onset of CNS pathology with concurrent accelerated motor impairment [1, [3] [4] [5] 9] . Homozygous line M83 +/+ A53T αS mice naturally develop a severe motor phenotype between 8 and 16 months that is associated with the formation of αS inclusions in the spinal cord, brain stem, thalamus, periaqueductal gray, and motor cortex [2] . Hemizygous M83 +/− mice do not begin to develop these phenotypes until 21 months or later [2] , but disease can be induced earlier by injection of CNS homogenates from affected M83 +/+ mice [5, 9] . Although purified αS protein fibrils can reproduce the effects seen with tissue homogenates [1, 3, 6, 8] , the Electronic supplementary material The online version of this article (doi:10.1007/s00401-015-1505-1) contains supplementary material, which is available to authorized users.
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pathology (Supplemental Fig. 3 ; Table 1 ). Sham-injected M83 +/− mice did not present any motor phenotype or αS inclusion pathology even at 330 DPI ( Fig. 1 ; Table 1 ). In M83 +/− mice that developed pathology from the injection of SC homogenates, the presence of αS inclusion pathology was observed in both neurons and glial cells near the injection site (Supplemental Fig. 2a, b) . However, distal from the injection site, most of the induced αS inclusion pathology was present in neurons (Supplemental Fig. 2c, d) .
Early pathology could also be induced in M83 +/− mice (135 DPI) by intrahippocampal injections of SC homogenates from αS-null mice (Supplemental Fig. 3 ; Table 1 ), demonstrating that the presence of αS was not required for SC homogenates to induce pathology. By comparison, intrahippocampal injections of cortical brain homogenates from NTg or αS-null mice did not induce αS inclusion pathology in a similar interval of time (Fig. 1 , Supplemental Fig. 3 ; Table 1 ).
Our studies demonstrate that intracerebral injection of SC homogenates from paralyzed G93A hSOD-1 mice, asymptomatic NTg mice, and asymptomatic mice lacking αS expression contains an entity that triggers the accelerated formation of αS inclusion pathology in M83 +/− mice. By comparison, cortical brain homogenates from NTg and αS-null mice do not contain such entities at levels sufficient to induce pathology rapidly. Whether cortical brain homogenates from asymptomatic mice contain such entities at any level will require further investigation. Importantly, the inability of the brain homogenates to induce αS pathology in M83 mice indicates that cross-contamination is an unlikely explanation for our results. There is little doubt that prion-like induction of αS pathology can occur because purified recombinant αS protein fibrilized in vitro can induce accelerated pathology when injected either peripherally or in the brain of M83 mice [1, 3, [6] [7] [8] . However, our study demonstrates that experiments in which tissue homogenates are used as the source of αS aggregates to induce αS pathology in M83 mice may require greater diligence in assigning an effect to any αS entities in the tissue. At this time, the identity of the component of the SC homogenates in NTg mice that accelerates the appearance of αS pathology in M83 +/− mice is unknown. Since SC homogenates contain much higher levels of myelinated white matter than brain cortical extracts, which did not induce αS inclusion pathology, it is likely that some component of the white matter is responsible for the accelerated pathology in the M83 mouse model. Table 1 Summary of the mice used in the studies All mice received bilateral hippocampal injections of the homogenates listed in the left column, except for sham-treated mice DPI days post-injection a One mouse from each of these cohorts with no overt phenotype was sacrificed at 105 DPI to assess the presentation of αS pathology. The mouse injected with SC homogenate from a NTg mouse presented with widespread αS pathology in the thalamus, periaqueductal gray, brain stem, and SC while the mouse treated with SC homogenate from a motor-impaired G93A hSOD-1 mouse had sparse αS pathology in the SC and brain stem Collectively, our findings demonstrate that intracerebral injection of homogenates from SC tissue can induce pathologic changes that mimic the prion-like pathologic changes that occur in the M83 mice when purified αS fibrils are injected to accelerate disease onset [1, 3, 6, 8] . +/− mice (e). Tissue sections were stained with antibodies to αS phosphorylated at Ser129 (EP1536Y and 81A), anti-αS (Syn 506), or anti-p62/sequestosome (a general marker of inclusion pathology) as indicated in each panel. Tissue sections were counterstained with hematoxylin. Scale bar 100 μm
